Literature DB >> 31144335

Clinical evaluation of tumour-infiltrating lymphocytes as a prognostic factor in patients with human papillomavirus-associated oropharyngeal squamous cell carcinoma.

Komkrit Ruangritchankul1,2, Ann Sandison1, Fiona Warburton3, Teresa Guerrero-Urbano4, Miguel Reis Ferreira4, Mary Lei4, Selvam Thavaraj1,5.   

Abstract

Clinical evaluation of tumour-infiltrating lymphocytes as a prognostic factor in patients with human papillomavirus-associated oropharyngeal squamous cell carcinoma AIMS: The majority of patients with human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OpSCC) have favourable survival outcomes, but a significant minority of individuals will die of their disease. There are currently no definitive criteria with which to identify HPV-associated OpSCC patients with poor outcomes. Recent reports suggest that quantitative evaluation of T-cell subpopulations in OpSCC may be of prognostic value, but the methods used have limited utility in a clinical diagnostic setting. We therefore sought to determine the clinical prognostic utility of tumour-infiltrating lymphocyte (TIL) evaluation in patients with HPV-associated OpSCC within the context of a diagnostic histopathology setting. METHODS AND
RESULTS: Representative diagnostic haematoxylin and eosin (H&E)-stained slides from 232 consecutive HPV-associated OpSCC patients were classified as containing a high (TILHi ; diffuse, lymphocytes in >80% of tumour and stroma), moderate (TILMod ; patchy, present in 20-80% of tumour and stroma) or low (TILLo ; sparse or absent, present in <20% of tumour and stroma) TILs. Interobserver reliability was assessed, and TIL category was then correlated with overall survival (OS) and disease-free survival (DFS). Univariate and multivariate analyses showed statistically significant differences in OS and DFS estimates when TILHi and TILMod patients were compared with TILLo patients (P < 0.0001 for TILHi versus TILLo ; P < 0.0001 for TILMod versus TILLo ). Statistical significance was retained when TILHi and TILMod patients were grouped into a single category (TILHi ) and compared with TILLo patients (P < 0.0001).
CONCLUSION: We demonstrate the prognostic utility of TILs in patients with HPV-associated OpSCC in clinical practice. A binary system classifying HPV-associated OpSCC into TILHi and TILLo on the basis of routine H&E staining stratifies patients into those with potentially favourable and unfavourable survival outcomes, respectively.
© 2019 John Wiley & Sons Ltd.

Entities:  

Keywords:  human papillomavirus; oropharyngeal; tumour-infiltrating lymphocytes

Year:  2019        PMID: 31144335     DOI: 10.1111/his.13873

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  5 in total

Review 1.  Development of head and neck pathology in Europe.

Authors:  Henrik Hellquist; Abbas Agaimy; Göran Stenman; Alessandro Franchi; Alfons Nadal; Alena Skalova; Ilmo Leivo; Nina Zidar; Roderick H W Simpson; Pieter J Slootweg; Juan C Hernandez-Prera; Alfio Ferlito
Journal:  Virchows Arch       Date:  2022-01-14       Impact factor: 4.064

Review 2.  Enhanced Radiation Sensitivity of Human Papillomavirus-Driven Head and Neck Cancer: Focus on Immunological Aspects.

Authors:  Mine Özcan-Wahlbrink; Christoph Schifflers; Angelika B Riemer
Journal:  Front Immunol       Date:  2019-12-03       Impact factor: 7.561

3.  Low PDL1 Expression in Tumour Infiltrating Lymphocytes Predicts Local Recurrence in Oral Squamous Cell Carcinoma.

Authors:  Narayana Subramaniam; Ajit Nambiar; Sujan Dhar; Krishnakumar Thankappan; Manzoor Koyakutty; Deepak Balasubramanian; Manjula Das; Subramania Iyer
Journal:  Indian J Surg Oncol       Date:  2021-04-27

Review 4.  Tumor-Infiltrating Lymphocytes in Head and Neck Cancer: Ready for Prime Time?

Authors:  Alhadi Almangush; Stijn De Keukeleire; Sylvie Rottey; Liesbeth Ferdinande; Tijl Vermassen; Ilmo Leivo; Antti A Mäkitie
Journal:  Cancers (Basel)       Date:  2022-03-18       Impact factor: 6.639

5.  Tumour-infiltrating lymphocytes in oropharyngeal cancer: a validation study according to the criteria of the International Immuno-Oncology Biomarker Working Group.

Authors:  Alhadi Almangush; Lauri Jouhi; Timo Atula; Caj Haglund; Antti A Mäkitie; Jaana Hagström; Ilmo Leivo
Journal:  Br J Cancer       Date:  2022-01-18       Impact factor: 9.075

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.